Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of “Moderate Buy” by Analysts

Vera Therapeutics, Inc. (NASDAQ:VERA) has earned an average rating of “Moderate Buy” from the twelve research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $79.00.

VERA has been the topic of several analyst reports. HC Wainwright boosted their target price on Vera Therapeutics from $90.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Evercore set a $91.00 target price on shares of Vera Therapeutics in a research note on Friday. Wolfe Research upgraded shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 target price for the company in a research note on Wednesday, March 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Monday, April 20th.

Vera Therapeutics Price Performance

Shares of VERA stock opened at $37.32 on Monday. The stock has a market cap of $2.68 billion, a price-to-earnings ratio of -6.74 and a beta of 0.96. The business’s fifty day moving average is $39.59 and its 200 day moving average is $40.61. Vera Therapeutics has a twelve month low of $18.76 and a twelve month high of $56.05. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period in the prior year, the firm earned ($0.81) earnings per share. Research analysts expect that Vera Therapeutics will post -5.9 EPS for the current fiscal year.

Insider Transactions at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 18,500 shares of the company’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $36.74, for a total value of $679,690.00. Following the completion of the sale, the chief executive officer directly owned 216,744 shares in the company, valued at $7,963,174.56. This represents a 7.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Laurence Matthew Skelton sold 1,582 shares of the company’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $66,412.36. Following the completion of the sale, the insider owned 64,218 shares of the company’s stock, valued at $2,695,871.64. This trade represents a 2.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 74,941 shares of company stock worth $3,096,592 over the last three months. 15.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of VERA. GAMMA Investing LLC boosted its holdings in Vera Therapeutics by 50.5% in the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after buying an additional 236 shares during the period. Los Angeles Capital Management LLC bought a new position in Vera Therapeutics in the 4th quarter worth $46,000. Quantbot Technologies LP bought a new position in Vera Therapeutics in the 2nd quarter worth $51,000. Aster Capital Management DIFC Ltd bought a new position in Vera Therapeutics in the 4th quarter worth $71,000. Finally, Tower Research Capital LLC TRC boosted its holdings in Vera Therapeutics by 192.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after buying an additional 2,757 shares during the period. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.